SCHEMBL12499716

SCHEMBL12499716

CN1CCN(Cc2cc3c(Oc4ccc(NC(=O)Nc5ccc(F)cc5)cc4)ncnc3[nH]2)CC1

nearest known ligand 0.56

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 11/20 0.56
KDR P35968 4/20 0.51
CSF1R P07333 2/20 0.49
MAPK14 Q16539 1/20 0.47
SRC P12931 1/20 0.47
FLT1 P17948 1/20 0.47
FLT4 P35916 1/20 0.47
CDK1 P06493 1/20 0.46
CDK2 P24941 1/20 0.46
CDK8 P49336 1/20 0.46
MET P08581 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1894491 0.90 FLT3 (0.54) FLT3KDRCSF1RMET
SCHEMBL12411688 0.83 FLT3 (0.57) FLT3KDRCSF1RMAPK14
SCHEMBL1889586 0.83 FLT3 (0.64) FLT3KDRCSF1RMAPK14
SCHEMBL14540935 0.82 CCNK (0.44) KDR
SCHEMBL1892088 0.76 FLT3 (0.65) FLT3KDRCSF1RMAPK14
SCHEMBL1895572 0.75 FLT3 (0.64) FLT3KDRCSF1RMAPK14
SCHEMBL1890715 0.75 FLT3 (0.58) FLT3KDRCSF1R
SCHEMBL12411691 0.74 EPHX2 (0.51) FLT3KDRFLT1FLT4MET
SCHEMBL1895590 0.74 CSF1R (0.64) FLT3KDRCSF1RMAPK14
SCHEMBL17229956 0.73 FLT3 (1.00) FLT3KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8372981-B2 Nitrogen-containing aromatic derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2013-02-12 US disclosed
US-7973160-B2 Nitrogen-containing aromatic derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-07-05 US disclosed
US-20110118470-A1 NITROGEN-CONTAINING AROMATIC DERIVATIVES FUNAHASHI YASUHIRO 2011-05-19 US disclosed
US-20100197911-A1 Nitrogen-Containing Aromatic Derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-05 US disclosed
US-20100197911-A1 Nitrogen-Containing Aromatic Derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-05 US disclosed
US-7612092-B2 Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective EISAI R & D MANAGEMENT CO., LTD. (JP) 2009-11-03 US disclosed
US-7612092-B2 Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective EISAI R & D MANAGEMENT CO., LTD. (JP) 2009-11-03 US disclosed
US-7253286-B2 Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective EISAI CO., LTD (JP) 2007-08-07 US disclosed
US-7253286-B2 Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective EISAI CO., LTD (JP) 2007-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197911-A1 Nitrogen-Containing Aromatic Derivatives GNG2, GCG, FRG1 FLT3 1153/4885KDR 2687/4885CSF1R 2007/4885
US-20110118470-A1 NITROGEN-CONTAINING AROMATIC DERIVATIVES GNG2, GCG, FRG1 FLT3 1310/4885KDR 2782/4885CSF1R 2032/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.